left-arrow right-arrow pinterest facebook google_plus linkedin

BTCRC GU15-023



Open | Phase IB and II 

Official Title:

Phase IB/II Study Of Concurrent Durvalumab And Radiation Therapy (Duart) Followed By Adjuvant Durvalumab In Patients With Urothelial Cancer (T2-4 N0-2 M0) Of The Bladder: Big Ten Cancer Research Consortium BTCRC-GU15-023

Study Purpose:

To determine how long patients with bladder cancer remain patient free and/or how well patients with bladder cancer respond to treatment when given Durvalumab during radiation therapy and after radiation therapy.


  • Radiation therapy (High energy X-rays that kill cancer cells)   
  • Immunotherapy: Durvalumab
  • Treatment: Therapy with Durvalumab IV every 4 weeks (2 doses) then Durvalumab IV every four weeks for up to 12 months.

Key Participation Requirements:


Male or Female


19 years and older


Muscle invasive and locally advanced bladder cancer.


Prior therapy: Previous therapy is permitted as long as it did not include an immunotherapy.

Patients must not be a candidate for surgery

Patients must not be able to receive treatment with Cisplatin (a chemotherapy treatment for Bladder Cancer)

Patients must sign an approved informed consent and authorization permitting release of personal health information.

Methodist Health System Trial Code:

BTCRC GU15-023

For more information, visit the U.S. National Library of Medicine clinical trial database.

To learn more about this clinical trial please contact us today!